Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
John A HeyJeremy Y YuSusan AbushakraJean F SchaeferAidan PowerPatrick KesslakMartin TolarPublished in: Drugs (2024)
https://clinicaltrials.gov/study/NCT04693520.